Abbott’s hepatitis drug displaying promising results in Phase II
Abbott had conducted a combination of experimental oral hepatitis C treatments in small group experiment. This Phase II trial combined ABT-450, Abbott’s protease inhibitor, with antiviral drug ritonavir together with its polymerase inhibitor ABT-333 and ribavirin. Patients were then checked 24 weeks later after the treatment and if they are tested negative or achieve an SVR24, they will be deemed cured from hepatitis C. More than 90% of the patients had achieved sustained virological response after 12 weeks of treatment.
To read original article, click here.
One of the conference tracks at BioPharma Asia 2013 will be Pharma Trials World Asia, featuring issues such as regulatory challenges, pharmacovigilance, clinical trials and drug safety in Asia! Contact Rebecca Koh at +65 6322 2725 or firstname.lastname@example.org to find out more about it! Visit our website here.